Cancer biotech MAIA Biotechnology files for a $15 million IPO
By Renaissance Capital, MAIA Biotechnology, a Phase 2 biotech developing targeted immunotherapies for cancer, filed on Monday with the SEC to raise up to $15 million in an initial public offering. The company’s lead candidate, THIO, is expected to enter Phase 2 human trials in Australia and Europe in the 1H22 for Non-Small Cell Lung[…]